Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Image Source: Unsplash
An Introduction
This article highlights the 10 largest clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week, in descending order, and YTD and their areas of focus, along with their latest news, analyses and commentary where available.
- **GH Research (GHRS): UP 9.5% during the second week of May; UP 120.5% YTD
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- *Exscientia (EXAI): UP 3.0% during the second week of May; DOWN 25.0% YTD
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Latest news, commentary and/or analysis:
- *Recursion Pharmaceuticals (RXRX): DOWN 2.7% during the second week of May; DOWN 12.8% YTD
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Latest news, commentary and/or analysis:
- *Absci Corporation (ABSI): DOWN 3.3% during the second week of May; UP 16.9% YTD
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Latest news, commentary and/or analysis: None
- *Schrödinger (SDGR): DOWN 4.0% during the second week of May; DOWN 36.5% YTD
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Latest news, commentary and/or analysis:
- *AbCellera Biologics (ABCL): DOWN 5.0% during the second week of May; DOWN 32.9% YTD
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Latest news, commentary and/or analysis:
- **Mind Medicine (MNMD): DOWN 7.3% during the second week of May; UP 7.4% YTD
- **atai Life Sciences (ATAI): DOWN 7.8% during the second week of May; UP 34.0% YTD
- **Compass Pathways (CMPS): DOWN 7.9% during the second week of May; DOWN 10.2% YTD
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, commentary and/or analysis:
- *Relay Therapeutics (RLAY): DOWN 8.8% during the second week of May; DOWN 41.7% YTD
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Latest news, commentary and/or analysis:
Summary
On average, the above 10 stocks were DOWN 2.9% during the second week of May and are now DOWN 10.3% YTD.
More By This Author:
Cronos Q1 Financial Metrics Show Improvement; Stock Climbs 3%
Canadian Cannabis LPs Portfolio Went Down 7% Last Week
American Cannabis MSOs Portfolio Down 5% On The Week
Disclosure: None
This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...
more
Comments
